Efficacy of brand-name vs. generic fluoxetine

Perspectives in Psychiatric Care

Volumn 39, Issue 3, 2003, Pages

  Shields, Brenda J ^a   Nahata, Milap C ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLARITIN D; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; GENERIC DRUG;

ADULT; CASE REPORT; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH INSURANCE; HUMAN; LETTER; MAJOR DEPRESSION; MENSTRUATION; PRESCRIPTION; PSYCHOSOCIAL WITHDRAWAL; SLEEP DISORDER; SOCIAL INTERACTION; SUICIDAL BEHAVIOR; SYMPTOM; TREATMENT OUTCOME;

EID: 0344861870     PISSN: 00315990     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2003.00122.x     Document Type: Letter

References (3)

1. Albrecht, J., & Adler, R. H. (2001). Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine® with Fluocim.® Swiss Medical Weekly, 131, 84.
2. Hovaguimian, T. (1998). Générique et obsessions ou obsession du générique. A propos d'un cas de rechute d'un trouble obsessionnel compulsif lors d'une substitution de la fluoxetine par un générique [Generics and obsessions, or obsession with generics: A case of obsessive-compulsive disorder following a substitution of fluoxetine with a generic]. Médecine et Hygiène, 2229, 2085-2087.
3. Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., et al. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30, 239-245.